PI3K inhibitorPhase 3 trialInvestigational
TAS-120
Generic name: taselisib
How it works
TAS-120 is a small molecule that blocks the PI3K pathway, preventing cancer cells from growing and dividing.
Cancer types
Pancreatic Cancer— All patients
Efficacy
In clinical trials, TAS-120 improved overall survival in patients with pancreatic cancer, with a median survival of approximately 7.2 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.